Vanda Pharmaceuticals (VNDA) Competitors $5.43 +0.27 (+5.23%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$5.50 +0.08 (+1.38%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VNDA vs. INVA, OPK, DVAX, ZBIO, GERN, MYGN, VSTM, RIGL, LXRX, and EBSShould you be buying Vanda Pharmaceuticals stock or one of its competitors? The main competitors of Vanda Pharmaceuticals include Innoviva (INVA), OPKO Health (OPK), Dynavax Technologies (DVAX), Zenas BioPharma (ZBIO), Geron (GERN), Myriad Genetics (MYGN), Verastem (VSTM), Rigel Pharmaceuticals (RIGL), Lexicon Pharmaceuticals (LXRX), and Emergent Biosolutions (EBS). These companies are all part of the "biotechnology" industry. Vanda Pharmaceuticals vs. Its Competitors Innoviva OPKO Health Dynavax Technologies Zenas BioPharma Geron Myriad Genetics Verastem Rigel Pharmaceuticals Lexicon Pharmaceuticals Emergent Biosolutions Innoviva (NASDAQ:INVA) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends. Is INVA or VNDA more profitable? Innoviva has a net margin of 10.44% compared to Vanda Pharmaceuticals' net margin of -32.90%. Innoviva's return on equity of 18.67% beat Vanda Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Innoviva10.44% 18.67% 9.92% Vanda Pharmaceuticals -32.90%-12.89%-10.47% Does the media prefer INVA or VNDA? In the previous week, Innoviva had 6 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 9 mentions for Innoviva and 3 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 0.68 beat Innoviva's score of 0.64 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Vanda Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation & earnings, INVA or VNDA? Innoviva has higher revenue and earnings than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInnoviva$358.71M3.07$23.39M$0.3156.39Vanda Pharmaceuticals$203.47M1.58-$18.90M-$1.13-4.81 Do analysts prefer INVA or VNDA? Innoviva presently has a consensus target price of $37.60, indicating a potential upside of 115.10%. Vanda Pharmaceuticals has a consensus target price of $16.50, indicating a potential upside of 203.87%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Vanda Pharmaceuticals is more favorable than Innoviva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Innoviva 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50Vanda Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Which has more risk & volatility, INVA or VNDA? Innoviva has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500. Comparatively, Vanda Pharmaceuticals has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Do insiders and institutionals believe in INVA or VNDA? 99.1% of Innoviva shares are owned by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. 2.3% of Innoviva shares are owned by company insiders. Comparatively, 10.0% of Vanda Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryInnoviva beats Vanda Pharmaceuticals on 11 of the 17 factors compared between the two stocks. Get Vanda Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VNDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VNDA vs. The Competition Export to ExcelMetricVanda PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$320.85M$3.35B$6.11B$10.54BDividend YieldN/A2.28%5.66%4.69%P/E Ratio-4.8122.2886.8426.71Price / Sales1.58265.33533.69203.04Price / CashN/A46.3226.3031.09Price / Book0.599.9012.606.57Net Income-$18.90M-$52.45M$3.30B$276.78M7 Day Performance10.59%5.05%3.54%1.96%1 Month Performance17.79%10.61%6.78%9.11%1 Year Performance17.28%25.03%71.47%31.60% Vanda Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VNDAVanda Pharmaceuticals4.2808 of 5 stars$5.43+5.2%$16.50+203.9%+17.3%$320.85M$203.47M-4.81290INVAInnoviva4.7844 of 5 stars$19.03+0.9%$42.75+124.6%-11.1%$1.19B$358.71M61.39100Positive NewsAnalyst DowngradeOPKOPKO Health4.3816 of 5 stars$1.47+1.4%$2.63+78.6%+4.7%$1.15B$713.10M-5.882,997DVAXDynavax Technologies4.5909 of 5 stars$9.66-1.2%$24.33+151.9%-8.3%$1.15B$277.25M-21.00350Positive NewsZBIOZenas BioPharma1.6212 of 5 stars$20.57+2.4%$36.67+78.3%N/A$846M$5M-5.79N/AGERNGeron2.928 of 5 stars$1.31+1.6%$3.79+189.0%-68.8%$823.04M$76.99M-10.0870MYGNMyriad Genetics3.7434 of 5 stars$7.24-6.0%$12.45+72.0%-69.6%$716.44M$837.60M-1.692,700VSTMVerastem2.4943 of 5 stars$8.64-2.8%$13.29+53.8%+203.1%$547.14M$10K-2.6350RIGLRigel Pharmaceuticals3.6542 of 5 stars$28.75+0.4%$38.20+32.9%+77.9%$513.55M$179.28M5.31160LXRXLexicon Pharmaceuticals3.0092 of 5 stars$1.39-0.7%$3.23+132.0%-16.6%$508.76M$31.08M-4.21140Positive NewsAnalyst UpgradeEBSEmergent Biosolutions4.3795 of 5 stars$8.93+0.2%$13.50+51.3%-2.5%$475.36M$1.04B3.642,420Positive News Related Companies and Tools Related Companies Innoviva Competitors OPKO Health Competitors Dynavax Technologies Competitors Zenas BioPharma Competitors Geron Competitors Myriad Genetics Competitors Verastem Competitors Rigel Pharmaceuticals Competitors Lexicon Pharmaceuticals Competitors Emergent Biosolutions Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VNDA) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vanda Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vanda Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
